Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
Technologies

Visulex® System

Aciont's DSP-Visulex® system is a non-invasive, safe and patient friendly technology that adjusts dosing with treatment time and formulation. Scleral-lens shaped applicator of DSP-Visulex improves drug delivery efficiency by maintaining and sealing the drug reservoir on the target location on the conjunctival surface. This minimizes the drug clearance on the eye surface and enhances drug delivery to the eye. DSP-Visulex technology can deliver significant amounts of drug to the posterior tissues of the eye in an animal model. Also, DSP-Visulex has demonstrated efficacy in the treatment of experimental autoimmune uveitis (EAU) in rabbit, both anterior and posterior sections.

The DSP-Visulex is an effective delivery system for both the front and the back of the eye. In designing our system, we have taken into account the easy insertion into the eye; how well it seals to the eye surface in a comfortable fashion; the use of biocompatible materials; and the importance of keeping the cornea hydrated. Our DSP-Visulex drug delivery system is easy to use and can be worn for 5 minutes on the eye (see the silent video below).



Essentially, the DSP-Visulex mitigates problems of frequent dosing of eye drops and problems associated with ocular injections such as bleeding, pain, risks of retinal detachment and infection. Patient compliance is a core of DSP-Visulex system. DSP-Visulex is currently in clinical trial phase 1/2.

Visulex-I, is a non-invasive ocular device using electroosmosis for macromolecule delivery to the posterior segment of the eye. Aciont has successfully delivered therapeutic relevant concentrations of AvastinĀ® (an anti-VEGF) in live animals to inhibit choroidal neovascularization. Such an optimized treatment offering could reduce the tremendous costs AMD therapy imposes on our health care system. Visulex-I is currently in the pre-clinical development.
Drug delivery improvements represent the next wave of back of the eye therapies